These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 25987173)

  • 1. Fabry disease and the heart.
    Seydelmann N; Wanner C; Störk S; Ertl G; Weidemann F
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):195-204. PubMed ID: 25987173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Fabry cardiomyopathy: models for the cardiologist.
    Weidemann F; Niemann M; Warnock DG; Ertl G; Wanner C
    Annu Rev Med; 2011; 62():59-67. PubMed ID: 21090963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Fabry cardiomyopathy - diagnostic approach and current treatment.
    Weidemann F; Ertl G; Wanner C; Krämer J
    Curr Pharm Des; 2015; 21(4):473-8. PubMed ID: 25483948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters.
    Koskenvuo JW; Hartiala JJ; Nuutila P; Kalliokoski R; Viikari JS; Engblom E; Penttinen M; Knuuti J; Mononen I; Kantola IM
    J Inherit Metab Dis; 2008 Jun; 31(3):432-41. PubMed ID: 18509742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
    Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
    Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease.
    Nguyen Dinh Cat A; Escoubet B; Agrapart V; Griol-Charhbili V; Schoeb T; Feng W; Jaimes E; Warnock DG; Jaisser F
    PLoS One; 2012; 7(5):e33743. PubMed ID: 22574107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rare presentation of Fabry disease as 'burnt-out' hypertrophic cardiomyopathy.
    Williams S; El-Medany A; Nightingale A; Ismail Y
    BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fabry disease.
    Yuasa T; Takenaka T; Higuchi K; Uchiyama N; Horizoe Y; Cyaen H; Mizukami N; Takasaki K; Kisanuki A; Miyata M; Ohishi M
    J Echocardiogr; 2017 Dec; 15(4):151-157. PubMed ID: 28674962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.
    Pisani A; Spinelli L; Sabbatini M; Andreucci MV; Procaccini D; Abbaterusso C; Pasquali S; Savoldi S; Comotti C; Cianciaruso B
    Am J Kidney Dis; 2005 Jul; 46(1):120-7. PubMed ID: 15983965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.
    Zamorano J; Serra V; Pérez de Isla L; Feltes G; Calli A; Barbado FJ; Torras J; Hernandez S; Herrera J; Herrero JA; Pintos G
    Eur J Echocardiogr; 2011 Sep; 12(9):671-7. PubMed ID: 21810826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy.
    Nordin S; Kozor R; Vijapurapu R; Augusto JB; Knott KD; Captur G; Treibel TA; Ramaswami U; Tchan M; Geberhiwot T; Steeds RP; Hughes DA; Moon JC
    Circ Cardiovasc Imaging; 2019 Dec; 12(12):e009430. PubMed ID: 31826677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Clinical-Pathologic Results of Enzyme Replacement Therapy in Prehypertrophic Fabry Disease Cardiomyopathy.
    Frustaci A; Verardo R; Galea N; Alfarano M; Magnocavallo M; Marchitelli L; Sansone L; Belli M; Cristina M; Frustaci E; Russo MA; Chimenti C
    J Am Heart Assoc; 2024 Apr; 13(8):e032734. PubMed ID: 38563373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
    Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
    Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
    Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
    Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Agalsidase Alfa Enzyme Replacement Therapy on Left Ventricular Hypertrophy on Electrocardiogram in a Female Patient with Fabry Disease.
    Nakamura K; Morita H; Takaya Y; Saito Y; Miyoshi T; Morinaga H; Sugiyama H; Wada J; Ito H
    Int Heart J; 2023 May; 64(3):502-505. PubMed ID: 37197914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiac manifestations of Anderson-Fabry disease and efficacy of enzyme replacement therapy].
    Hagège A
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S238-42. PubMed ID: 21211672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study.
    Imbriaco M; Pisani A; Spinelli L; Cuocolo A; Messalli G; Capuano E; Marmo M; Liuzzi R; Visciano B; Cianciaruso B; Salvatore M
    Heart; 2009 Jul; 95(13):1103-7. PubMed ID: 19372091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F; Wanner C
    J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.